Immunic’s (IMUX) “Buy” Rating Reaffirmed at D. Boral Capital
D. Boral Capital reaffirmed their buy rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a report released on Thursday morning,Benzinga reports. They currently have a $10.00 target price on the stock. A number of other analysts have also recently commented on the stock. William Blair reiterated an “outperform” rating on shares of Immunic […]
D. Boral Capital reaffirmed their buy rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a report released on Thursday morning,Benzinga reports. They currently have a $10.00 target price on the stock. A number of other analysts have also recently commented on the stock. William Blair reiterated an “outperform” rating on shares of Immunic […]
